NCT02616289

Brief Summary

The investigators hypothesize that the absorption of topically applied EFA-containing emollient (SSO) into the skin and thence into the bloodstream in children with SAM will improve skin barrier function and accelerate weight gain and clinical rehabilitation beyond that possible through normal standard-of-care

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
212

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 26, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2016

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

January 9, 2020

Status Verified

December 1, 2019

Enrollment Period

4 years

First QC Date

November 18, 2015

Last Update Submit

January 7, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • changes of body weight

    Body weight will be measured after 10 days of intervention

    Baseline and 10th day

Secondary Outcomes (7)

  • Time to discharge from acute illnesses

    through study completion, an average of 5 days

  • Reduction of rate of nosocomial infections between cases and controls

    through study completion, an average of 10 days

  • Reduction in TEWL

    baseline and 10th day

  • Serum CRP level

    Baseline and 10th day

  • Serum Cytokines level

    Baseline and 10th day

  • +2 more secondary outcomes

Study Arms (2)

Emollient

EXPERIMENTAL

Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.

Other: Topical emollient (Sun Flower seed oil)

Control

NO INTERVENTION

Routine Standard of care only for severe acute malnutrition.

Interventions

3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.

Emollient

Eligibility Criteria

Age2 Months - 24 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Parent or legal guardian is willing and able to provide written informed consent for the subject to take part in the trial and comply with an inpatient stay of at least 10 days.
  • Children aged 2-24 months inclusive diagnosed with SAM (weight-for-length Z score \<-3 or bilateral pedal edema) admitted in the Dhaka Hospital of icddr,b, Dhaka, Bangladesh
  • Willing to suspend usual home skin care treatments for the duration of study

You may not qualify if:

  • Consent refusal
  • Life threatening health conditions such as septic shock and altered consciousness on admission; congenital problems (congenital heart disease or known metabolic disorders, chromosomal abnormalities, renal failure, etc.); any known chronic disease including tuberculosis, HIV infection
  • History of drug or other allergy or any condition that may complicate the interpretation of safety or efficacy such as dermatitis which, in the opinion of the investigator, contraindicates participation in the trial, or know hypersensitivity to SSO
  • The child is in care (no longer looked after by their parent or legal guardian)
  • Participation in another study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dhaka Hospital, icddr,b

Dhaka, 1212, Bangladesh

Location

Related Publications (3)

  • Fischer N, Darmstadt GL, Shahunja KM, Crowther JM, Kendall L, Gibson RA, Ahmed T, Relman DA. Topical emollient therapy with sunflower seed oil alters the skin microbiota of young children with severe acute malnutrition in Bangladesh: A randomised, controlled study. J Glob Health. 2021 Jul 17;11:04047. doi: 10.7189/jogh.11.04047. eCollection 2021.

  • Shahunja KM, Sevin DC, Kendall L, Ahmed T, Hossain MI, Mahfuz M, Zhu X, Singh K, Singh S, Crowther JM, Gibson RA, Darmstadt GL. Effect of topical applications of sunflower seed oil on systemic fatty acid levels in under-two children under rehabilitation for severe acute malnutrition in Bangladesh: a randomized controlled trial. Nutr J. 2021 Jun 6;20(1):51. doi: 10.1186/s12937-021-00707-3.

  • Shahunja KM, Ahmed T, Hossain MI, Mahfuz M, Kendall L, Zhu X, Singh K, Crowther JM, Singh S, Gibson RA, Darmstadt GL. Topical emollient therapy in the management of severe acute malnutrition in children under two: A randomized controlled clinical trial in Bangladesh. J Glob Health. 2020 Jun;10(1):010414. doi: 10.7189/jogh.10.010414.

MeSH Terms

Conditions

Child Nutrition DisordersMalnutrition

Interventions

Emollients

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Dermatologic AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

  • K M Shahunja, MBBS

    International Centre for Diarrhoeal Disease Research, Bangladesh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Clinical Trial in two treatment arms
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2015

First Posted

November 26, 2015

Study Start

January 1, 2016

Primary Completion

December 31, 2019

Study Completion

December 31, 2019

Last Updated

January 9, 2020

Record last verified: 2019-12

Locations